The company received approval from the Foreign Investment Promotion Board (FIPB) to sell its OTC division to GlaxoSmithKline Consumer. The stock was down 1.8 percent at Rs. 6,134.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
